{"doc_id": "si-2022-0402-reg-1", "parent_doc_id": "si-2022-0402", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 402 of 2022", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2022, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2022” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2022 (2) collective citation medicinal product (prescription control supply) regulation 2003 2022 includes regulation", "start_char": 618, "end_char": 908, "source_path": "downloads\\2022\\2022_0401.pdf", "extraction_method": "pdfminer", "checksum": "sha256:8a4d79b12506b63d1ba78b4d9abf42495c5297dd6c45b97c1a2cfb7dfcc2720b", "cross_refs": []}
{"doc_id": "si-2022-0402-reg-2", "parent_doc_id": "si-2022-0402", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 402 of 2022", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2022, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and \nControl of Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2022” means the Medicinal Products (Prescription and Control \nof Supply (Amendment) (No. 3) Regulations 2022 (S.I. No. 84 of 2022).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2022 mean medicinal product (prescription control supply (amendment) (no 3) regulation 2022 (s.i no 84 2022)", "start_char": 908, "end_char": 1221, "source_path": "downloads\\2022\\2022_0401.pdf", "extraction_method": "pdfminer", "checksum": "sha256:8a4d79b12506b63d1ba78b4d9abf42495c5297dd6c45b97c1a2cfb7dfcc2720b", "cross_refs": []}
{"doc_id": "si-2022-0402-reg-3", "parent_doc_id": "si-2022-0402", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 402 of 2022", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2022, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations \n\nof 2022) to the Principal Regulations is amended— \n\n(a) \n\n(b) \n\nin column 5 of the entry for the medicinal product “Comirnaty \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)”, by substituting “pregnancy, \nliving arrangements or otherwise” for “pregnancy or otherwise”, \nin column 5 of the entry for the medicinal product “Spikevax \n(previously Covid-19 Vaccine Moderna) dispersion for injection \nCOVID-19 mRNA Vaccine \n(nucleoside modified)”, by \nsubstituting “pregnancy, living arrangements or otherwise” for \n“pregnancy or otherwise”, and \n\n(c) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty 10 micrograms/dose concentrate \nfor dispersion for \ninjection COVID-19 mRNA Vaccine \n(nucleoside modified) Paediatric pack” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health, subject to informed consent \nbeing obtained from a parent or guardian. \nAdministered as a course of 2 doses (0.2 mL each) at least 19 \ndays apart. \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 2nd August, 2022. \n\n \n \n \n \n \n \n \n \n \n\f[402] 3 \n\nAn additional dose should be administered to children aged 5 to \n11 years who are immunocompromised at least 28 days after the \nsecond dose to complete the primary series. \nNotwithstanding any directions to the contrary in the summary \nof product characteristics, a booster dose may be administered to \nchildren aged 5 to 11 years who— \n(a) \n\nare immunocompromised and have already received an \nadditional dose of a Covid-19 vaccine, or \n\n(b) have already received a primary vaccine course against \nCovid-19 and have become immunocompromised since \nthe administration of that primary vaccine course. \n\nThe additional and booster doses should be administered in such \nvolumes, at such intervals, in such manner and in such order of \nprioritisation (whether by reference to age, immune status, \nliving arrangements or otherwise), as may be specified in such \nrecommendations or guidelines.”.", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2022) principal regulation amended-- (a) (b) column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) substituting pregnancy living arrangement otherwise pregnancy otherwise column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) substituting pregnancy living arrangement otherwise pregnancy otherwise (c) substituting text column 5 entry medicinal product comirnaty 10 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health subject informed consent obtained parent guardian administered course 2 dos (0.2 ml each) least 19 day apart notice making statutory instrument published iris oifigiuil 2nd august 2022 402 3 additional dose administered child aged 5 11 year immunocompromised least 28 day second dose complete primary series notwithstanding direction contrary summary product characteristic booster dose may administered child aged 5 11 year who-- (a) immunocompromised already received additional dose covid-19 vaccine (b) already received primary vaccine course covid-19 become immunocompromised since administration primary vaccine course additional booster dos administered volume interval manner order prioritisation (whether reference age immune status living arrangement otherwise) may specified recommendation guideline", "start_char": 1221, "end_char": 3447, "source_path": "downloads\\2022\\2022_0401.pdf", "extraction_method": "pdfminer", "checksum": "sha256:8a4d79b12506b63d1ba78b4d9abf42495c5297dd6c45b97c1a2cfb7dfcc2720b", "cross_refs": []}
{"doc_id": "si-2022-0402-reg-4", "parent_doc_id": "si-2022-0402", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 402 of 2022", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2022, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\nof 2022) to the Principal Regulations is amended— \n\n(a) \n\n(b) \n\nin column 5 of the entry for the medicinal product “Comirnaty \nconcentrate for dispersion for injection COVID-19 mRNA \nVaccine (nucleoside modified)”, by substituting “pregnancy, \nliving arrangements or otherwise” for “pregnancy or otherwise”, \nin column 5 of the entry for the medicinal product “Spikevax \n(previously Covid-19 Vaccine Moderna) dispersion for injection \nCOVID-19 mRNA Vaccine \n(nucleoside modified)”, by \nsubstituting “pregnancy, living arrangements or otherwise” for \n“pregnancy or otherwise”, and \n\n(c) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty 10 micrograms/dose concentrate \nfor dispersion for \ninjection COVID-19 mRNA Vaccine \n(nucleoside modified) Paediatric pack” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health, subject to informed consent \nbeing obtained from a parent or guardian. \nAdministered as a course of 2 doses (0.2 mL each) at least 19 \ndays apart. \nAn additional dose should be administered to children aged 5 to \n11 years who are immunocompromised at least 28 days after the \nsecond dose to complete the primary series. \nNotwithstanding any directions to the contrary in the summary \nof product characteristics, a booster dose may be administered to \nchildren aged 5 to 11 years who— \n(a) \n\nare immunocompromised and have already received an \nadditional dose of a Covid-19 vaccine, or \n\n \n \n \n\f4 [402] \n\n(b) have already received a primary vaccine course against \nCovid-19 and have become immunocompromised since \nthe administration of that primary vaccine course. \n\nThe additional and booster doses should be administered in such \nvolumes, at such intervals, in such manner and in such order of \nprioritisation (whether by reference to age, immune status, \nliving arrangements or otherwise), as may be specified in such \nrecommendations or guidelines.”. \n\nGIVEN under my Official Seal, \n\n29 July, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n\f[402] 5", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2022) principal regulation amended-- (a) (b) column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) substituting pregnancy living arrangement otherwise pregnancy otherwise column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) substituting pregnancy living arrangement otherwise pregnancy otherwise (c) substituting text column 5 entry medicinal product comirnaty 10 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health subject informed consent obtained parent guardian administered course 2 dos (0.2 ml each) least 19 day apart additional dose administered child aged 5 11 year immunocompromised least 28 day second dose complete primary series notwithstanding direction contrary summary product characteristic booster dose may administered child aged 5 11 year who-- (a) immunocompromised already received additional dose covid-19 vaccine 4 402 (b) already received primary vaccine course covid-19 become immunocompromised since administration primary vaccine course additional booster dos administered volume interval manner order prioritisation (whether reference age immune status living arrangement otherwise) may specified recommendation guideline  given official seal 29 july 2022 stephen donnelly minister health 402 5", "start_char": 3447, "end_char": 5675, "source_path": "downloads\\2022\\2022_0401.pdf", "extraction_method": "pdfminer", "checksum": "sha256:8a4d79b12506b63d1ba78b4d9abf42495c5297dd6c45b97c1a2cfb7dfcc2720b", "cross_refs": []}
{"doc_id": "si-2022-0402-explanatory-note", "parent_doc_id": "si-2022-0402", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 402 of 2022", "title": "(Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines", "year": 2022, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to amend the relevant schedules in relation \nto the COVID-19 vaccines to provide for booster doses of Comirnaty COVID19 Vaccine, Paediatric Formulation to immunocompromised persons aged 5 to \n11 and to clarify that booster doses of the mRNA vaccines may be prioritised \non the basis of living arrangements. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 4) Regulations 2022. \n\n \n \n \n \n \n \n \n \n\f6 [402] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(SH-435) 75. 7/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation amend relevant schedule relation covid-19 vaccine provide booster dos comirnaty covid19 vaccine paediatric formulation immunocompromised person aged 5 11 clarify booster dos mrna vaccine may prioritised basis living arrangement regulation may cited medicinal product (prescription control supply) (amendment) (no 4) regulation 2022 6 402 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (sh-435) 75 7 22 propylon", "start_char": 5675, "end_char": 6885, "source_path": "downloads\\2022\\2022_0401.pdf", "extraction_method": "pdfminer", "checksum": "sha256:8a4d79b12506b63d1ba78b4d9abf42495c5297dd6c45b97c1a2cfb7dfcc2720b", "cross_refs": []}
